All In MedTech

FDA Clearance Tracker · P230036-S010

Esprit™ BTK Everolimus Eluting Resorbable Scaffold System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 16, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Apr 16, 2025

Approved

Time to decision

27 days

Received Mar 20, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P230036-S010
Device name
Esprit™ BTK Everolimus Eluting Resorbable Scaffold System
Applicant location
Santa Clara, CA
Received
Mar 20, 2025
Decided
Apr 16, 2025
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P230036

Device type

Device class
Class III
Specialty
Cardiology

Every decision under product code NXW

FDA's approval statement

As written in FDA's record.

Approval of the revised protocol for the Esprit BTK-PAS: New Enrollment Study submitted in P230036/S010.

Source documents

Other decisions for ABBOTT MEDICAL

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.